SpringerLink
Log in

Pegylated liposomal doxorubicin in combination with vinorelbine as salvage treatment in pretreated patients with advanced breast cancer: a multicentre phase II study

  • Original Article
  • Published:
Cancer Chemotherapy and Pharmacology Aims and scope Submit manuscript

Abstract

Purpose: To investigate the activity and tolerance of pegylated liposomal doxorubicin in combination with vinorelbine in pretreated patients with metastatic breast cancer. Patients and treatment: Thirty-six women with metastatic breast cancer were enrolled. The median age was 64 years, 80% of the patients had a performance status of 0–1, 30 (83%) had visceral disease and 83% had received prior taxanes while 50% anthracyclines. Treatment consisted of pegylated liposomal doxorubicin (40 mg/m2 on day 1) and vinorelbine (25 mg/m2 on days 1 and 15) every 4 weeks. Results: In an intention-to-treat analysis 2 (6%) complete and 12 (33%) partial responses were observed (overall response rate 39%; 95% CI: 23–54.8%); 8 (22%) and 14 (39%) patients experienced stable and progressive disease, respectively. The median TTP was 6.5 months and the median survival time 14.2 months. The 1-year survival rate was 54.1%. Grade 3 and 4 neutropenia occurred in 21 (58%) patients, grade 3–4 anemia in four (11%) and grade 4 thrombocytopenia in one (3%). Two (6%) patients developed febrile neutropenia. Non-hematologic toxicity was mild and easily manageable. There was no clinically important cardiac toxicity or treatment-related deaths. Conclusions: The combination of pegylated liposomal doxorubicin and vinorelbine is an active and well tolerated salvage regimen in patients with metastatic breast cancer which merits further evaluation.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Subscribe and save

Springer+ Basic
EUR 32.99 /Month
  • Get 10 units per month
  • Download Article/Chapter or Ebook
  • 1 Unit = 1 Article or 1 Chapter
  • Cancel anytime
Subscribe now

Buy Now

Price includes VAT (Thailand)

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

Similar content being viewed by others

References

  1. Perez DJ, Harvey VJ, Robinson BA et al (1991) Randomized comparison of single agent doxorubicin and epirubicin as first-line cytotoxic chemotherapy in advanced breast cancer. J Clin Oncol 9:2148–2152

    PubMed  CAS  Google Scholar 

  2. von Hoff DD, Layard MW, Basa P et al (1979) Risk factors for doxorubicin-induced congestive heart failure. Ann Int Med 91:710–717

    PubMed  Google Scholar 

  3. Bonadonna G, Gianni L, Santoro A et al (1993) Drugs ten years later: Epirubicin. Ann Oncol 4:359–369

    PubMed  CAS  Google Scholar 

  4. Speyer J, Wasserheit C (1998) Strategies for reduction of anthracycline cardiac toxicity. Sem Oncol 25:525–537

    CAS  Google Scholar 

  5. Gabizon A, Martin F (1997) Polyethylene glycol-coated (pegylated) liposomal doxorubicin. Rational for use in solid tumors. Drugs 54:15–21

    Article  PubMed  CAS  Google Scholar 

  6. Symon Z, Peyser A, Tzemach D (1999) Selective delivery of doxorubicin to patients with breast carcinoma metastases by stealth liposomes. Cancer 86:72–78

    Article  PubMed  CAS  Google Scholar 

  7. Alberts DS, Garcia DJ (1997) Safety aspects of pegylated liposomal doxorubicin in patients with cancer. Drugs 54:30–35

    PubMed  CAS  Google Scholar 

  8. Lyass O, Uziely B, Ben-Yozef R (2000) Correlation of toxicity with pharmacokinetics of pegylated doxorubicin in metastatic breast carcinoma. Cancer 89:1037–1047

    Article  PubMed  CAS  Google Scholar 

  9. Safra T, Muggia F, Jeffers S et al (2000) Pegylated liposomal doxorubicin (doxil): reduced clinical cardiotoxicity in patients reaching or exceeding cumulative doses of 500 mg/m2. Ann Oncol 11:1029–1033

    Article  PubMed  CAS  Google Scholar 

  10. Ranson MR, Carmichael J, O’Byrne K et al (1997) Treatment of advanced breast cancer with sterically stabilized liposomal doxorubicin: results of a multicenter phase II trial. J Clin Oncol 15:3185–3191

    PubMed  CAS  Google Scholar 

  11. Shapiro CL, Ervin T, Welles L et al (1999) Phase II trial of high-dose liposome-encapsulated doxorubicin with granulocyte colony-stimulating factor in metastatic breast cancer. J Clin Oncol 17:1435–1441

    PubMed  CAS  Google Scholar 

  12. Batist G, Ramakrishnan G, Rao CS et al (2001) Reduced cardiotoxicity and preserved antitumor efficacy of liposomal-encapsulated doxorubicin and cyclophosphamide compared with conventional doxorubicin and cyclophosphamide in a randomized, multicenter trial of metastatic breast cancer. J Clin Oncol 19:1444–1454

    PubMed  CAS  Google Scholar 

  13. Androulakis N, Kouroussis Ch, Mavroudis D et al (2002) Phase I study of weekly paclitaxel and liposomal doxorubicin in patients with advanced solid tumors. Eur J Cancer 38:1992–1997

    PubMed  CAS  Google Scholar 

  14. Mavroudis D, Kouroussis Ch, Kakolyris S et al (2002) Phase I study of paclitaxel (Taxol) and pegylated liposomal doxorubicin (Caelyx) administered every 2 weeks in patients with advanced solid tumors. Oncology 62:216–222

    Article  PubMed  CAS  Google Scholar 

  15. Jones S, Winer E, Vogel C et al (1995) Randomized comparison of vinorelbine and melphalan in anthracycline-refractory advanced breast cancer. J Clin Oncol 13:2567–2574

    PubMed  CAS  Google Scholar 

  16. Weber BL, Vogel C, Jones S et al (1995) Intravenous vinorelbine as first-line and second-line therapy in advanced breast cancer. J Clin Oncol 13:2722–2730

    PubMed  CAS  Google Scholar 

  17. Zelek L, Barthier S, Riofrio M et al (2001) Weekly vinorelbine is an effective palliative regimen after failure with anthracyclines and taxanes in metastatic breast carcinoma. Cancer 92:2267–2272

    Article  PubMed  CAS  Google Scholar 

  18. Spielmann M, Dorval T, Turpin F et al (1994) Phase II trial of vinorelbine/doxorubicin as first-line therapy of advanced breast cancer. J Clin Oncol 12:1764–1770

    PubMed  CAS  Google Scholar 

  19. Norris B, Pritchard KI, James K et al (2000) Phase III comparative study of vinorelbine combined with doxorubicin versus doxorubicin alone in disseminated metastatic/recurrent breast cancer: National Cancer Institute of Canada Clinical Trials Group Study MA8. J Clin Oncol 18:2385–2394

    PubMed  CAS  Google Scholar 

  20. Burstein HJ, Ramirez MJ, Petros WP et al (1999) Phase I study of Doxil and vinorelbine in metastatic breast cancer. Ann Oncol 10:113–116

    Article  PubMed  Google Scholar 

  21. Martin M, Garcia-Donas J, Casado A et al (2004) Phase II study of pegylated liposomal doxorubicin plus vinorelbine in breast cancer with previous anthracycline exposure. Clin Breast Cancer 5:353–357

    Article  PubMed  CAS  Google Scholar 

  22. Ajani JA, Welch SR, Raber MN et al (1990) Compressive criteria for assessing therapy-inducing toxicity. Cancer Invest 8:147–159

    Article  PubMed  CAS  Google Scholar 

  23. Miller AB, Hoogstraten BB, Staquet M et al (1981) Reporting results of cancer treatment. Cancer 47:207–214

    Article  PubMed  CAS  Google Scholar 

  24. A’Hern RP (2001) Sample size tablets for exact phase II clinical trials. Stat Med 20:859–866

    Article  PubMed  CAS  Google Scholar 

  25. Kaplan EL, Meier P (1959) Nonparametric estimation from incomplete observations. J Am Stat Assoc 53:457–481

    Article  Google Scholar 

  26. Cox DR (1970) The analysis of binary data. London, Methuen

  27. Bontenbal M, Andersson M, Wildiers J et al (1998) Doxoxrubicin vs epirubicin, report of a second-line randomized phase II/III study in advanced breast cancer. EORTC Breast Cancer Cooperative Group. Br J Cancer 77:2257–2263

    PubMed  CAS  Google Scholar 

  28. Rivera E, Valero V, Esteva FJ et al (2002) Lack of activity of stealth liposomal doxorubicin in the treatment of patients with anthracycline-resistant breast cancer. Cancer Chemother Pharmacol 49:299–302

    Article  PubMed  CAS  Google Scholar 

  29. Rimassa L, Carnaghi C, Garassino I et al (2003) Unexpected low efficacy of stealth liposomal doxorubicin (Caelyx) and vinorelbine in metastatic breast cancer. Breast Cancer Res Treat 77:185–188

    Article  PubMed  CAS  Google Scholar 

  30. Alexopoulos CG, Rigatos G, Efremidis AP et al (1999) A phase II study of the effectiveness of docetaxel (Taxotere) in women with advanced breast cancer previously treated with polychemotherapy. Hellenic Cooperative Interhospital Group in Oncology. Cancer Chemother Pharmacol 44:253–258

    Article  PubMed  CAS  Google Scholar 

  31. Ramos M, Gonzalez-Ageitos A, Amenedo M et al (2003) Weekly docetaxel as second-line therapy for patients with advanced breast cancer resistant to previous anthracycline treatment. J Chemother 15:192–197

    Article  PubMed  CAS  Google Scholar 

  32. Mavroudis D, Malamos N, Alexopoulos A et al (1999) Salvage chemotherapy in anthracycline-pretreated breast cancer patients with docetaxel and gemcitabine: a multicenter phase II trial of the Greek Breast Cancer Cooperative Group. Ann Oncol 10:211–215

    Article  PubMed  CAS  Google Scholar 

  33. Donadio M, Ardine M, Berruti A et al (2003) Gemcitabine and vinorelbine as second-line treatment in patients with metastatic breast cancer: A phase II study. Cancer Chemother Pharmacol 52:147–152

    Article  PubMed  CAS  Google Scholar 

  34. Morabito A, Filippelli G, Palmeri S et al (2003) The combination of gemcitabine and vinorelbine is an active regimen as second-line therapy in patients with metastatic breast cancer pretreated with taxanes and/or anthracyclines: a phase I-II study. Breast Cancer Res Treat 78:29–36

    Article  PubMed  CAS  Google Scholar 

  35. Spielmann M, Dorval T, Turpin F et al (1994) Phase II trial of vinorelbine/doxorubicin as first-line therapy of advanced breast cancer. J Clin Oncol 12:1764–1770

    PubMed  CAS  Google Scholar 

  36. Baldini E, Tibaldi C, Chiavacci F et al (1998) Epirubicin/vinorelbine as first line therapy in metastatic breast cancer. Breast Cancer Res Treat 49:129–134

    Article  PubMed  CAS  Google Scholar 

  37. Nistico C, Garufi C, Barni S et al (1999) Phase II study of epirubicin and vinorelbine with granulocyte colony-stimulating factor: a high-activity, dose-dense weekly regimen for advanced breast cancer. Ann Oncol 10:937–942

    Article  PubMed  CAS  Google Scholar 

  38. Vici P, Colucci G, Gebbia V et al (2002) First-line treatment with epirubicin and vinorelbine in metastatic breast cancer. J Clin Oncol 20:2689–2694

    Article  PubMed  CAS  Google Scholar 

  39. Pawlicki M, Rolski J, Zaluski J et al (2002) A phase II study of intravenous navelbine and doxorubicin combination in previously untreated advanced breast carcinoma. Oncologist 7:205–209

    Article  PubMed  CAS  Google Scholar 

  40. Gebbia V, Mauceri G, Fallica G et al (2002) Pegylated liposomal doxorubicin with vinorelbine in metastatic breast carcinoma. A phase I-II clinical investigation. Oncology 63:23–30

    Article  PubMed  CAS  Google Scholar 

  41. Serin D, Verrill M, Jones A et al (2005) Vinorelbine alternating oral and intravenous plus epirubicin in first-line therapy of metastatic breast cancer: results of a multicentre phase II study. Br J Cancer 92:1989–1996

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Medical Oncology, University General Hospital of Heraklion, PO BOX 1352, 71110, Heraklion, Crete, Greece

    Alexandros Ardavanis, Dimitris Mavroudis, Kostas Kalbakis, Nikolaos Malamos, Kostas Syrigos, Lambros Vamvakas, Athanasios Kotsakis, Nikolaos Kentepozidis, Charalambos Kouroussis, Sophia Agelaki & Vassilis Georgoulias

Authors
  1. Alexandros Ardavanis
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Dimitris Mavroudis
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Kostas Kalbakis
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Nikolaos Malamos
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Kostas Syrigos
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Lambros Vamvakas
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Athanasios Kotsakis
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Nikolaos Kentepozidis
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Charalambos Kouroussis
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. Sophia Agelaki
    View author publications

    You can also search for this author in PubMed Google Scholar

  11. Vassilis Georgoulias
    View author publications

    You can also search for this author in PubMed Google Scholar

Consortia

for the Breast Cancer Committee of the Hellenic Oncology Research Group (HORG)

Corresponding author

Correspondence to Vassilis Georgoulias.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Ardavanis, A., Mavroudis, D., Kalbakis, K. et al. Pegylated liposomal doxorubicin in combination with vinorelbine as salvage treatment in pretreated patients with advanced breast cancer: a multicentre phase II study. Cancer Chemother Pharmacol 58, 742–748 (2006). https://doi.org/10.1007/s00280-006-0236-3

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00280-006-0236-3

Keywords

Search

Navigation